QQ客服 官方微博 反馈留言

浏览/检索结果: 共15条，第1-10条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China 期刊论文 THORACIC CANCER, 2021 作者:  Shi, Yuequan;  Fang, Jian;  Zhou, Chengzhi;  Liu, Anwen;  Wang, Yan 收藏  |  浏览/下载：63/0  |  提交时间：2022/01/25 advanced lung cancer  immune checkpoint inhibitors  immune-related adverse events  real-world data   The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study 期刊论文 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 作者:  Wang, Wenxian;  Gu, Xiaodong;  Wang, Liping;  Pu, Xingxiang;  Feng, Huijing 收藏  |  浏览/下载：27/0  |  提交时间：2022/01/10 Non-small cell lung cancer  PD-L1  Immune checkpoint inhibitor  Immune-related adverse event   Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors 期刊论文 BIOORGANIC CHEMISTRY, 2021, 卷号: 116, 页码: 13 作者:  Meng, Xiang-Dong;  Gao, Li-Xin;  Wang, Zhi-Jia;  Feng, Bo;  Zhang, Chun 收藏  |  浏览/下载：30/0  |  提交时间：2021/12/01 2,5-diphenyl-1,3,4-oxadiazole derivatives  SHP2  Inhibitors  Structure-activity relationships (SAR)   Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition 期刊论文 CHINESE CHEMICAL LETTERS, 2021, 卷号: 32, 期号: 6, 页码: 1929-1936 作者:  Gao, Jing;  Zhang, Hanwu;  Zhou, Fengqi;  Hou, Bo;  Chen, Meiwan 收藏  |  浏览/下载：17/0  |  提交时间：2021/08/17 Cancer immunotherapy  siRNA delivery  Acid-activatible micelleplex  CDK4  6 inhibitor  PD-L1 knockdown   Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy 期刊论文 BRITISH JOURNAL OF PHARMACOLOGY, 2021, 页码: 20 作者:  Liu, Chenglong;  Zhou, Feilong;  Yan, Ziqin;  Shen, Lian;  Zhang, Xichen 收藏  |  浏览/下载：26/0  |  提交时间：2021/06/11 immunotherapy  PD-1/PD-L1  TGF-beta  tumour immune microenvironment   Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy 期刊论文 NEOPLASIA, 2021, 卷号: 23, 期号: 3, 页码: 281-293 作者:  Wang, Fengling;  Ye, Wenling;  Wang, Shuang;  He, Yongxing;  Zhong, Haiyang 收藏  |  浏览/下载：32/0  |  提交时间：2021/12/10 PD-1  PD-L1  Inhibitor  APBC  Cancer immunotherapy   Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China 期刊论文 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 作者:  Zhang, Xiangyu;  Zeng, Liang;  Li, Yizhi;  Xu, Qinqin;  Yang, Haiyan 收藏  |  浏览/下载：29/0  |  提交时间：2021/03/15 Anlotinib  Immunotherapy  Programmed death 1 inhibitor  Lung cancer   Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden 期刊论文 FRONTIERS IN ONCOLOGY, 2021, 卷号: 10 作者:  Wang, Rong;  Yang, Yuchen;  Ye, Wei-Wu;  Xiang, Jianxing;  Chen, Songan 收藏  |  浏览/下载：44/0  |  提交时间：2021/04/26 breast cancer  immunotherapy  biomarker  TMB  NGS  molecular monitoring   Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer 期刊论文 NANO TODAY, 2021, 卷号: 36, 页码: 12 作者:  Zhou, Fengqi;  Gao, Jing;  Xu, Zhiai;  Li, Tianliang;  Gao, Ang 收藏  |  浏览/下载：23/0  |  提交时间：2021/06/11 Tumor microenvironment  Prodrug nanovesicles  Cancer immunotherapy  Immunogenic cell death  Adaptive immune resistance   Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration 期刊论文 CLINICAL THERAPEUTICS, 2021, 卷号: 43, 期号: 2, 页码: 396-409 作者:  Zhang, Yi-fan;  Liu, Yan-mei;  Yu, Chen;  Wang, Ya-ting;  Zhan, Yan 收藏  |  浏览/下载：67/0  |  提交时间：2021/05/24 diabetes  henagliflozin  pharmacodynamics  pharmacokinetics  SGLT-2 inhibitors